SUPPORT HOTLINE (888) 901-2226
Donate Now

BRIEF TITLE: Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab (MK-3475) in Combination With Vorinostat in Patients With Advanced Renal or Urothelial Cell Carcinoma

A Phase I/Ib, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab (MK-3475) in Combination With Vorinostat in Patients With Advanced Renal or Urothelial Cell Carcinoma


  • Org Study ID: IUSCC-0551
  • Secondary ID:
  • NCT ID: NCT02619253
  • NCT Alias:
  • Sponsor: Roberto Pili - Other
  • Source: Indiana University

Brief Summary

Primary objective: To assess the safety and tolerability of pembrolizumab in combination with vorinostat in patients with advanced renal or urothelial cell carcinoma in order to select the recommended Phase 2 dose (RP2D). Secondary objectives: (1) To evaluate the overall safety profile of pembrolizumab in combination with vorinostat; (2) To assess the anti-tumor activity (i.e. objective response rate, progression-free survival) of pembrolizumab in combination with vorinostat in patients with advanced renal or urothelial cell carcinoma; (3) To characterize PD-L1/2, immune cell subsets, and miRs in tumor and/or blood.

Detailed Description


This is a Phase I/Ib, open-label, safety, and pharmacodynamics study of pembrolizumab in
combination with vorinostat in patients with advanced renal or urothelial cell carcinoma.
This clinical study will be composed of a Dose Finding Phase and an Expansion Phase. The Dose
Finding Phase will estimate the Recommended Phase II Dose (RP2D) in patients with advanced
renal and urothelial cell carcinoma patients. The Dose Finding Phase will lead to the
identification of an Expansion Test Dose for pembrolizumab in combination with vorinostat.
The Expansion Test Dose will be the Recommended Phase II Dose (RP2D) (i.e. the highest tested
dose that is declared safe and tolerable by the Investigators and Sponsor). Patients will be
treated with oral vorinostat every day for 14 days, and with pembrolizumab at the fixed dose
of 200 mg IV. Each cycle is every 21 days. Two dose levels of vorinostat will be tested in
2-patient cohorts according to the 3 + 3 standard design (100 mg and 200 mg). 200 mg dose
represents 50% of the recommended vorinostat dose as single agent.

For the Dose Finding Phase (Combination Phase), the starting dose level of vorinostat will be
100 mg by mouth (PO) every day for 14 days, with 7 days break. The first dose level will have
a minimum of 3 patients treated (unless the first 2 patients experience dose-limiting
toxicities (DLTs) before the 3rd patient is enrolled).

Once the RP2D is identified, the Dose Expansion Phase will be opened. During the Dose
Expansion Phase, the study will have a run-in phase with sequential single-agents and then
the combination phase. The reason for the run-in phase during dose expansion is to obtain
data on the immunomodulatory effects of vorinostat separately from pembrolizumab. Thirty
patients with prior treatments will be enrolled in two expansion cohorts: 15 anti-PD1 naive
patients and 15 anti-PD1 resistant patients (defined as patients with transient clinical
response or without clinical response to prior immune-checkpoint inhibition).

Overal Status Start Date Phase Study Type
Recruiting January 14, 2016 Phase 1 Interventional

Primary Outcomes:

Primary Outcome 1 - Measure: Find Recommended Phase 2 Dose (RP2D) of pembrolizumab in combination with vorinostat

Primary Outcome 1 - Time Frame: 18 months

Condition:

  • Renal Cell Carcinoma
  • Urinary Bladder Neoplasms

Eligibility

Criteria:
All subjects must have previously treated either locally advanced or metastatic renal or
urothelial cell carcinoma to be eligible for participation.

Subject Inclusion Criteria

In order to be eligible for participation in this trial, the subject must:

1. Be willing and able to provide written informed consent for the trial.

2. Be 18 years of age jor older on day of signing informed consent.

3. Have measurable disease based on RECIST 1.1.

4. Have a performance status of 0-2 on the ECOG Performance Scale.

5. Demonstrate adequate organ function. All screening labs should be performed within 10
days of treatment initiation.

6. Female subject of childbearing potential should have a negative urine or serum
pregnancy test within 72 hours prior to receiving the first dose of study medication.
If the urine test is positive or cannot be confirmed as negative, a serum pregnancy
test will be required.

7. Subjects of childbearing potential should be willing to use 2 methods of contraception
for the course of the study through 120 days after the last dose of study medication.
Acceptable methods of birth control include: abstinence, partner with previous
vasectomy, placement of an intrauterine device (IUD), condom with spermicidal
foam/gel/film/cream/suppository, diaphragm or cervical vault cap, or hormonal birth
control (pills or injections). NOTE: Females are considered of childbearing potential
unless they are surgically sterile (they have undergone a hysterectomy, bilateral
tubal ligation, or bilateral oophorectomy) or they are postmenopausal (a woman who is
≥45 years of age and has not had menses for greater than 1 year).

8. Male subjects without a previous vasectomy should agree to use an adequate method of
contraception (i.e. abstinence, condom with spermicidal foam/gel/film/cream) starting
with the first dose of study therapy through 120 days after the last dose of study
therapy.

9. Subjects have archival tumor tissue available or are willing to undergo a baseline
biopsy prior to treatment.

10. Subjects with urothelial carcinoma must be platinum-resistant (i.e., treatment-free
interval 6< months)

11. Subjects with a history of diabetes mellitus must have HgbA1c level of _<7% upon study
entry.

Subject Exclusion Criteria

The subject must be excluded from participating in the trial if the subject:

1. Is currently participating and receiving study therapy or has participated in a study
of an investigational agent and received study therapy or used an investigational
device within 4 weeks of the first dose of treatment.

2. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any
other form of immunosuppressive therapy within 7 days prior to the first dose of trial
treatment.

3. Has active TB (Bacillus Tuberculosis)

4. Hypersensitivity to pembrolizumab or any of its excipients.

5. Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to Cycle 1
Day 1 or who has not recovered (i.e. ≤ Grade 1 or at baseline) from adverse events due
to agents administered more than 4 weeks earlier.

6. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy
within 2 weeks prior to Cycle 1 Day 1 or who has not recovered (i.e. ≤ Grade 1 or at
baseline) from adverse events due to a previously administered agent.

- Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and
may qualify for the study.

- Note: If subject received major surgery, they must have recovered adequately from
the toxicity and/or complications from the intervention prior to starting
therapy.

7. Has a known additional malignancy that is progressing or requires active treatment.
Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the
skin that has undergone potentially curative therapy or in situ cervical cancer.

8. Has known active central nervous system (CNS) metastases and/or carcinomatous
meningitis. Subjects with previously treated brain metastases may participate provided
they are stable (without evidence of progression by imaging for at least four weeks
prior to the first dose of trial treatment and any neurologic symptoms have returned
to baseline), have no evidence of new or enlarging brain metastases, and are not using
steroids for at least 7 days prior to trial treatment. This exception does not include
carcinomatous meningitis which is excluded regardless of clinical stability.

9. Has active autoimmune disease that has required systemic treatment in the past 2 years
(i.e. with use of disease modifying agents, corticosteroids or immunosuppressive
drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid
replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
form of systemic treatment.

10. Has known history of, or any evidence of active, non-infectious pneumonitis.

11. Has an active infection requiring systemic therapy.

12. Has a history or current evidence of any condition, therapy, or laboratory abnormality
that might confound the results of the trial, interfere with the subject's
participation for the full duration of the trial, or is not in the best interest of
the subject to participate, in the opinion of the treating investigator.

13. Has known psychiatric or substance abuse disorders that would interfere with
cooperation with the requirements of the trial.

14. Is pregnant or breastfeeding, or expecting to conceive or father children within the
projected duration of the trial, starting with the pre-screening or screening visit
through 120 days after the last dose of trial treatment.

15. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent (only
Cohort A).

16. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).

17. Has known active Hepatitis B (e.g. HBsAg reactive) or Hepatitis C (e.g. HCV RNA
[qualitative] is detected).

18. Has received a live vaccine within 30 days of planned start of study therapy.
Show More

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Official Information

Name: Roberto Pili, MD

Role: Principal Investigator

Affiliation: Indiana University School of Medicine, Indiana University Simon Cancer Center

Overall Contact

Name: Marietta Moore, RN

Phone: 317-274-7477

Email:

Locations

Facility Status Contact
USC/Norris Comprehensive Cancer Center
Los Angeles, California 90033
United States
Recruiting Charis Barg, RN
323-865-0845
charis.barg@med.usc.edu
Indiana University Hospital
Indianapolis, Indiana 46202
United States
Recruiting Marietta Moore, RN
317-274-7477
marlmoor@iu.edu
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana 46202
United States
Recruiting Marietta Moore, RN
317-274-7477
marlmoor@iu.edu
IU Health Central Indiana Cancer Centers (CICC)
Indianapolis, Indiana 46219
United States
Recruiting Deb Racster, RN
317-727-6549
dracster@iuhealth.org
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland 21205
United States
Recruiting Connie Collins
410-955-1017
ccolli23@jhmi.edu